8-K: Calidi Biotherapeutics Divests Nova Cell for $6M

Calidi Biotherapeutics, Inc. has sold its 75% equity interest in subsidiary Nova Cell, Inc. for $6 million, aiming for $0.5 million in annual G&A expense reductions.

Summary

• Calidi Biotherapeutics, Inc. (the Company) entered into a Stock Repurchase Agreement (SRA) and Material Purchase Agreement (MPA) with its majority-owned subsidiary, Nova Cell, Inc., on October 27, 2025.
• The Company sold and transferred 22,500,000 shares of Nova Cell common stock, representing 75% of Nova Cell's equity interest and 100% of the Company's ownership, for a purchase price of $6,000,000.
• The purchase price was satisfied in part by the cancellation of indebtedness of $1,214,864 under a September 17, 2024 promissory note, net of specified offsets.
• The balance of $4,785,136 is Deferred Consideration, payable after closing through contingent payments.
• Deferred Consideration payments include a percentage of gross proceeds from Nova Cell's Qualified Capital Raises (equity or debt financing of at least $1,000,000) and a royalty percentage of Nova Cell's Gross Revenue.
• Upon full satisfaction of the Deferred Consideration, an ongoing royalty at a fixed percentage of Covered Gross Revenue attributable to specific materials will be payable quarterly for 10 years from Nova Cell's first product sale.
• Following the closing, Nova Cell is no longer a subsidiary of the Company.
• The Company estimates it will realize $0.5 million per year in general and administrative expense reductions as a result of the transaction.
• The MPA amends and supersedes the parties' July 28, 2024 Intellectual Property Assignment Agreement and provides for the sale and transfer of specific purchased materials to Nova Cell.
• Nova Cell assumed certain defined liabilities and agreed to a Prohibited Use covenant, including a prohibition on any uses relating to oncolytic viruses for the purchased materials.
• Calidi Biotherapeutics will retain stocks of certain cell lines for its own use.

Sentiment

Score: 7

Explanation: The divestiture is a strategic move that reduces Calidi's general and administrative expenses and cancels existing debt, providing immediate financial benefits. While future upside from Nova Cell is now contingent, the transaction allows for a more focused operational strategy. The contingent nature of a significant portion of the payment introduces some uncertainty, but the overall impact appears to be a positive step towards streamlining the business.

Positives

• Expected annual general and administrative expense reductions of $0.5 million.
• Cancellation of $1,214,864 in indebtedness owed by Calidi Biotherapeutics to Nova Cell.
• Streamlines corporate structure by divesting a subsidiary, potentially allowing for greater focus on core operations.
• Potential for future revenue through deferred consideration payments and ongoing royalties from Nova Cell's activities.

Negatives

• Loss of 75% equity interest and full ownership of Nova Cell, meaning Calidi Biotherapeutics will no longer directly benefit from Nova Cell's full growth potential.
• A significant portion of the $6,000,000 purchase price ($4,785,136) is deferred and contingent on Nova Cell's future capital raises and revenue generation.
• The ongoing royalty payment only commences after the deferred consideration is fully satisfied and is limited to a 10-year term from Nova Cell's first product sale.

Risks

• The realization of the Deferred Consideration and Additional Royalty Consideration is contingent on Nova Cell's ability to secure Qualified Capital Raises and generate Gross Revenue/Covered Gross Revenue.
• Certain identified information in the SRA and MPA has been omitted or redacted, which may limit full transparency.
• Nova Cell is subject to a 'Prohibited Use' covenant, restricting the use of purchased materials for purposes related to oncolytic viruses, which could limit its market opportunities.
• The assignment of PSC Data within the Purchased Materials is subject to limitations and third-party rights under existing agreements, potentially affecting Nova Cell's full utilization.

Future Outlook

Calidi Biotherapeutics expects to realize $0.5 million in annual G&A expense reductions. The company will receive deferred consideration payments and ongoing royalties from Nova Cell, contingent on Nova Cell's future capital raises and revenue generation. Calidi will also provide transition services to Nova Cell for 90 days post-closing.

Management Comments

• We estimate we will realize $0.5 million per year in general and administrative expense reductions as a result of the transaction.

Industry Context

Divestitures of non-core assets or subsidiaries are common strategic moves in the biotechnology industry, often undertaken to streamline operations, reduce overhead, focus resources on key pipeline assets, or generate capital. This transaction allows Calidi Biotherapeutics to potentially reallocate resources and reduce G&A expenses, while retaining a contingent financial interest in Nova Cell's future success.

Comparison to Industry Standards

• NA

Corporate Governance

Related Party Transactions

• The transaction involves Calidi Biotherapeutics, Inc. and its majority-owned subsidiary, Nova Cell, Inc., making it a related-party transaction.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value through reduced G&A expenses and a more focused business strategy, though direct upside from Nova Cell's growth is now limited to contingent payments and royalties.
• Employees: The agreement includes provisions for 'Conversion Fees' if R&D employees are hired between the Seller and Corporation within one year, impacting employee mobility and recruitment costs.
• Nova Cell: Becomes an independent entity, assuming certain liabilities and gaining full control over the purchased materials, subject to specific use restrictions.

Next Steps

• Calidi Biotherapeutics will provide reasonable transition and knowledge-transfer services to Nova Cell for 90 days from the closing date.
• Nova Cell will make deferred consideration payments to Calidi Biotherapeutics based on future Qualified Capital Raises and Gross Revenue.
• Nova Cell will make ongoing royalty payments to Calidi Biotherapeutics after the deferred consideration is fully satisfied, for a period of 10 years from Nova Cell's first product sale.

Key Dates

Recommendation

The divestiture of Nova Cell is a significant strategic restructuring for Calidi Biotherapeutics, aimed at streamlining operations and reducing G&A expenses. While the transaction provides immediate financial benefits through debt cancellation and potential future revenue streams from royalties and contingent payments, it also means Calidi will no longer directly control or fully benefit from Nova Cell's future growth. The long-term implications for Calidi's core business and overall financial performance require further evaluation, making a 'hold' recommendation appropriate as investors await more clarity on the company's refocused strategy and the realization of the contingent payments.

Keywords

Calidi Biotherapeutics, Nova Cell, Divestiture, Subsidiary Sale, Biotech, Biotherapeutics, SEC Filing, 8-K, Asset Disposition, Stock Repurchase, Promissory Note, Royalty Agreement, Cell Lines, R&D Materials